单位：[1]Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China[2]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[3]Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[4]Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China[5]Dalian Med Univ, Hosp 2, Dept Oncol, Dalian, Peoples R China[6]Zhejiang Univ, Med Sch, Affiliated Hosp 1, Hangzhou, Peoples R China浙江大学医学院附属第一医院[7]Peking Union Med Coll Hosp, Beijing, Peoples R China[8]Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[9]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China[10]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[11]Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou, Peoples R China[12]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[13]Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China[14]Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China[15]Jilin Univ, Bethune Hosp 1, Jilin, Jilin, Peoples R China[16]ChangHai Hosp, Shanghai, Peoples R China[17]Shandong Univ, Qilu Hosp, Jinan, Peoples R China[18]Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China[19]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China[20]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China[21]Innovent Biol Inc, Suzhou, Peoples R China[22]Innovent Biol Inc, Beijing, Peoples R China
出处：
ISSN：
基金：
Innovent Biologics, Inc.; China National Major Project for New Drug Innovation; CAMS Innovation Fund for Medical Sciences (CIFMS)
Su Hang,Song Yongping,Jiang Wenqi,et al.Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):
APA：
Su, Hang,Song, Yongping,Jiang, Wenqi,Sun, Xiuhua,Qian, Wenbin...&Wang, Shuyan.(2020).Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA：
Su, Hang,et al."Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)
医学